Skip to content
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Medical Genetics

Building Your Care Team and Long-Term Support

At a Glance

Individuals with Legius syndrome have a normal life expectancy and an excellent long-term prognosis. Care focuses on building a multidisciplinary medical team to provide targeted support and accommodations for learning, ADHD, and executive function challenges.

Managing Legius syndrome is less about intensive medical screening and more about providing a supportive environment to learn, work, and grow [1][2]. Because this condition is a RASopathy—affecting the same communication pathway in the brain as several other conditions—the best care comes from a team that understands how to manage these specific neurodevelopmental needs [3][4].

Building Your Medical Care Team

While Legius syndrome does not require the heavy tumor monitoring associated with NF1, a “team approach” ensures your physical and developmental health is optimized [1][4].

  • Medical Geneticist: This specialist usually leads the team. They confirm the diagnosis through SPRED1 variant analysis and provide long-term guidance [2][5].
  • Neurologist: Since there is a slight (3–5%) risk of epilepsy (seizures), a neurologist can provide a baseline evaluation and monitor for any unusual activity [6].
  • Developmental Specialist / Psychologist: This professional is key for managing ADHD, learning disabilities, or social communication challenges across both childhood and adulthood [7][8].
  • Ophthalmologist: A baseline eye exam is often recommended to confirm the absence of Lisch nodules or other NF1-related eye signs, which helps solidify the Legius diagnosis [1][9].

Navigating School, Work, and Support

Individuals with Legius syndrome often have varied needs; some might experience significant ADHD while others have only mild learning challenges [1][10]. To ensure success:

  1. Request Accommodations: For children, secure an IEP (Individualized Education Program) or a 504 Plan [11]. Adults can similarly request workplace accommodations for ADHD or executive function challenges. Use the SPRED1 mutation diagnosis as the medical documentation.
  2. Neuropsychological Testing: A formal evaluation can identify specific areas where the brain might struggle (such as “working memory” or “processing speed”) so that teachers or employers can tailor their expectations and support [8][7].
  3. Strengths-Based Approach: Focus on areas of natural strength. Utilizing these strengths helps build the confidence needed to tackle more challenging tasks [12].

Genetic Counseling and the Family

Understanding how Legius syndrome is passed down is vital for family planning and managing the health of relatives.

  • Inheritance: Legius syndrome follows an autosomal dominant inheritance pattern [1][2]. This means if a person has the mutation, there is a 50% chance of passing it to each child.
  • Spontaneous (De Novo) Mutations: It is critical to know that a person can have Legius syndrome even if neither parent has the condition. In these cases, the SPRED1 mutation occurs spontaneously for the first time in that individual (known as a de novo mutation) [1]. You do not need a family history to have Legius syndrome.
  • Cascade Testing: If a person is found to have the inherited mutation, “cascade testing” for other at-risk relatives (parents, siblings, or cousins) is often recommended to clarify their health risks [13][14].

Timeline of Symptoms and Long-Term Outlook

Understanding the timeline of Legius syndrome can help set expectations:

  • Infancy to Early Childhood: Café-au-lait spots and skinfold freckling appear [2].
  • School Age: Learning challenges, working memory deficits, or ADHD may become noticeable as academic demands increase [15].
  • Adulthood: Skin manifestations remain, and individuals may develop benign lipomas (fatty lumps under the skin) [16]. Adult ADHD management may be required.

The long-term prognosis for individuals with Legius syndrome is excellent [1][2].

  • Normal Life Expectancy: There is no evidence that Legius syndrome shortens life expectancy [17].
  • Standard Health: Management is focused on standard age-appropriate screenings and symptom-directed support rather than invasive tumor surveillance [18][19].

For ongoing support, consider connecting with patient advocacy groups, such as the Children’s Tumor Foundation, which provides resources and community connections for individuals living with Legius syndrome and other RASopathies.

Back to Home.

Common questions in this guide

What kind of doctors should be on a Legius syndrome care team?
A typical care team is led by a medical geneticist and may include a neurologist, a developmental specialist or psychologist to manage learning challenges, and an ophthalmologist for a baseline eye exam.
Can my child get school accommodations for Legius syndrome?
Yes, children with Legius syndrome can often secure an Individualized Education Program (IEP) or a 504 Plan. Medical documentation of the SPRED1 mutation can help establish the need for support with ADHD or learning disabilities.
Is Legius syndrome always inherited from a parent?
Yes, it follows an autosomal dominant inheritance pattern, meaning a parent with the condition has a 50% chance of passing it on. However, the mutation can also occur spontaneously in a person with no family history of the condition.
Who should be tested for Legius syndrome if I am diagnosed?
If you are diagnosed with an inherited SPRED1 mutation, cascade testing is usually recommended for at-risk relatives. This can include your parents, siblings, or children to clarify their genetic status and health risks.
What is the life expectancy for someone with Legius syndrome?
The long-term prognosis is excellent. There is no evidence that Legius syndrome shortens life expectancy, and medical management focuses on standard health screenings rather than invasive tumor monitoring.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Which local specialist should lead the multidisciplinary care team (e.g., a medical geneticist or a neurologist)?
  2. 2.Can you provide medical documentation of the Legius diagnosis to help establish an IEP, 504 plan, or workplace accommodation?
  3. 3.Given the genetics of the condition, which family members should we prioritize for cascade testing?
  4. 4.What is the process for coordinating with a developmental specialist if we notice new behavioral or learning challenges?
  5. 5.Are there any local patient advocacy groups or support networks you recommend for adults and families with RASopathies?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    Novel causative variants in Legius syndrome: SPRED1 Genotype spectrum expansion.

    Chelleri C, Brolatti N, De Marco P, et al.

    American journal of medical genetics. Part A 2024; (194(12)):e63824 doi:10.1002/ajmg.a.63824.

    PMID: 39031930
  2. 2

    Legius Syndrome and its Relationship with Neurofibromatosis Type 1.

    Denayer E, Legius E

    Acta dermato-venereologica 2020; (100(7)):adv00093 doi:10.2340/00015555-3429.

    PMID: 32147744
  3. 3

    RASopathies for Radiologists.

    Handa A, Tsujioka Y, Nishimura G, et al.

    Radiographics : a review publication of the Radiological Society of North America, Inc 2024; (44(5)):e230153 doi:10.1148/rg.230153.

    PMID: 38602868
  4. 4

    RASopathies: Dermatologists' viewpoints.

    Palit A, Inamadar AC

    Indian journal of dermatology, venereology and leprology 2022; (88(4)):452-463.

    PMID: 35138057
  5. 5

    Clinical and Genetic Findings in Children with Neurofibromatosis Type 1, Legius Syndrome, and Other Related Neurocutaneous Disorders.

    Giugliano T, Santoro C, Torella A, et al.

    Genes 2019; (10(8)) doi:10.3390/genes10080580.

    PMID: 31370276
  6. 6

    Epilepsy in Legius syndrome: Coincidence or causation?

    Medina Lemus A, Boelman C, Myers KA

    American journal of medical genetics. Part A 2024; (194(6)):e63547 doi:10.1002/ajmg.a.63547.

    PMID: 38268057
  7. 7

    Impaired instrumental learning in Spred1-/- mice, a model for a rare RASopathy.

    Borrie SC, Horner AE, Yoshimura A, et al.

    Genes, brain, and behavior 2021; (20(5)):e12727 doi:10.1111/gbb.12727.

    PMID: 33624414
  8. 8

    MEK inhibition ameliorates social behavior phenotypes in a Spred1 knockout mouse model for RASopathy disorders.

    Borrie SC, Plasschaert E, Callaerts-Vegh Z, et al.

    Molecular autism 2021; (12(1)):53 doi:10.1186/s13229-021-00458-2.

    PMID: 34311771
  9. 9

    The absence that makes the difference: choroidal abnormalities in Legius syndrome.

    Tucci A, Saletti V, Menni F, et al.

    Journal of human genetics 2017; (62(11)):1001-1004 doi:10.1038/jhg.2017.78.

    PMID: 28747691
  10. 10

    The first Slovak Legius syndrome patient carrying the SPRED1 gene mutation.

    Sekelska M, Briatkova L, Olcak T, et al.

    General physiology and biophysics 2017; (36(2)):205-210 doi:10.4149/gpb_2016032.

    PMID: 28150585
  11. 11

    Cell type-specific roles of RAS-MAPK signaling in learning and memory: Implications in neurodevelopmental disorders.

    Ryu HH, Lee YS

    Neurobiology of learning and memory 2016; (135()):13-21 doi:10.1016/j.nlm.2016.06.006.

    PMID: 27296701
  12. 12

    Neurodevelopmental Aspects of RASopathies.

    Kim YE, Baek ST

    Molecules and cells 2019; (42(6)):441-447 doi:10.14348/molcells.2019.0037.

    PMID: 31250618
  13. 13

    Building a family network from genetic testing.

    Leppig KA, Thiese HA, Carrel D, et al.

    Molecular genetics & genomic medicine 2017; (5(2)):122-129 doi:10.1002/mgg3.259.

    PMID: 28361098
  14. 14

    Population-based genetic testing of asymptomatic women for breast and ovarian cancer susceptibility.

    Rowley SM, Mascarenhas L, Devereux L, et al.

    Genetics in medicine : official journal of the American College of Medical Genetics 2019; (21(4)):913-922 doi:10.1038/s41436-018-0277-0.

    PMID: 30254378
  15. 15

    Genetic basis of neurofibromatosis type 1 and related conditions, including mosaicism.

    Legius E, Brems H

    Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery 2020; (36(10)):2285-2295 doi:10.1007/s00381-020-04771-8.

    PMID: 32601904
  16. 16

    The RASopathies: Biology, genetics and therapeutic options.

    Longo JF, Carroll SL

    Advances in cancer research 2022; (153()):305-341 doi:10.1016/bs.acr.2021.07.007.

    PMID: 35101235
  17. 17

    Moyamoya syndrome in a child with Legius syndrome: Introducing a cerebral vasculopathy to the SPRED1 phenotype?

    Pabst L, Carroll J, Lo W, Truxal KV

    American journal of medical genetics. Part A 2021; (185(1)):223-227 doi:10.1002/ajmg.a.61921.

    PMID: 33078527
  18. 18

    Genomic ascertainment to quantify prevalence and cancer risk in adults with pathogenic and likely pathogenic germline variants in RASopathy genes.

    Kim J, Ney G, Frone MN, et al.

    medRxiv : the preprint server for health sciences 2024; doi:10.1101/2024.10.09.24314324.

    PMID: 39802765
  19. 19

    SPRED proteins and their roles in signal transduction, development, and malignancy.

    Lorenzo C, McCormick F

    Genes & development 2020; (34(21-22)):1410-1421 doi:10.1101/gad.341222.120.

    PMID: 33872193

This page provides general information about building a care team and long-term support for Legius syndrome. Always consult your medical geneticist or healthcare provider for personalized medical advice and family planning.

Get notified when new evidence is published on Legius syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.